IMBB Researchers revealed that DNA damage triggers the release of cytoplasmic ssDNAs leading to chronic inflammation in mice. The team has developed a therapeutic strategy to deliver recombinant nucleases in vivo and remove cytoplasmic ssDNAs, alleviating inflammation.
